Nanobiotix (NBTX) Equity Average: 2021-2025

  • Nanobiotix's Equity Average fell 36.63% to $61.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $61.6 million, marking a year-over-year decrease of 36.63%. This contributed to the annual value of $86.8 million for FY2024, which is N/A change from last year.
  • Nanobiotix's Equity Average amounted to $61.6 million in Q2 2025, which was down 25.52% from $82.7 million recorded in Q4 2024.
  • Over the past 5 years, Nanobiotix's Equity Average peaked at $154.5 million during Q2 2021, and registered a low of $61.6 million during Q2 2025.
  • Moreover, its 3-year median value for Equity Average was $72.5 million (2023), whereas its average is $75.8 million.
  • As far as peak fluctuations go, Nanobiotix's Equity Average spiked by 49.48% in 2024, and later tumbled by 36.63% in 2025.
  • Nanobiotix's Equity Average (Quarterly) stood at $132.8 million in 2021, then plummeted by 34.49% to $101.2 million in 2022, then crashed by 35.77% to $72.5 million in 2023, then rose by 14.04% to $82.7 million in 2024, then crashed by 36.63% to $61.6 million in 2025.
  • Its Equity Average was $61.6 million in Q2 2025, compared to $82.7 million in Q4 2024 and $97.2 million in Q2 2024.